Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062360 · ClinicalTrials.gov registry record · Phase 3
Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,016
- Enrollment target
NCT01062360: Completed Phase 3 study, sponsored by Bayer.
NCT01062360 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,016 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01062360, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,016 participants
- Enrollment target
Study Summary
The purpose of this study is compare efficacy and tolerability of a fixed combination, containing 500 mg Acetylsalicylic acid and 30 mg Pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion.
Interventions
- DRUG Placebo
- DRUG Acetylsalicylic Acid (Aspirin, BAYE4465)
- DRUG Pseudoephedrine
- DRUG Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,016 participants |
| Start Date | 2005-12-23 |
| Est. Completion | 2007-05-14 |
| Phase | Phase 3 |
What the finished NCT01062360 record still lists
NCT01062360 is an interventional study that assigns participants to a tested intervention. Its 1,016 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01062360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01062360 about?
NCT01062360 is a clinical study titled "Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine". The purpose of this study is compare efficacy and tolerability of a fixed combination, containing 500 mg Acetylsalicylic acid and 30 mg Pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion.
What is the current status of trial NCT01062360?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,016 participants. The study started on 2005-12-23. Estimated completion is 2007-05-14.
What interventions are being tested in trial NCT01062360?
The interventions under investigation include: Placebo (DRUG), Acetylsalicylic Acid (Aspirin, BAYE4465) (DRUG), Pseudoephedrine (DRUG), Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine (DRUG).
Who is sponsoring clinical trial NCT01062360?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01062360's enrollment target sits among peer trials
1,016 294th of 2000 higher than 1,707 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI